UNSPSC 51352202: Broparestrol

This classification denotes a therapeutic estrogen with the molecular formula C22H19Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7U06D381UQ, chemically known as 2-brom-1-(4-ethylphenyl)-1,2-diphenylethylen but generally known as broparestrol, which bears US NIH Compound Identifier 3032769. European Medicines Agency schedules Broparestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05926MIG. The term BROPARESTROL is an International Non-Proprietary Name.

UNSPSC 51352202 Broparestrol, a Commodity code, encompasses active pharmaceutical ingredients and finished dosage forms that state and local health systems, correctional facilities, and other public-sector medical providers source through cooperative purchasing agreements and direct competitive procurements. State and local governments buying under this code typically acquire generic pharmaceuticals and over-the-counter products through multistate cooperative vehicles or individual agency RFPs, with vendors required to maintain FDA compliance, current Good Manufacturing Practices (cGMP) certification, and Drug Supply Chain Security Act (DSCSA) compliance. The issuing-body mix includes state departments of administration and multistate cooperative purchasing alliances; individual school districts, counties, and municipalities source through those cooperative vehicles rather than independently.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement and serving participating jurisdictions including Oregon, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to establish multiple contracts effective July 1, 2026. Vendors must supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and submit detailed product information including National Drug Codes, SKUs, UPCs, and manufacturing locations; evaluations weight price competitiveness at 75 percent, with fixed pricing (10 percent), price format compliance (5 percent), EDI capability (5 percent), and 3 percent administrative-fee acceptance (5 percent) comprising the remainder. Vendors must maintain contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place, carry specified insurance coverage (commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, professional liability of $2,000,000), and accept performance penalties of $200 to $1,500 per violation. The contract term is two years for new vendors, with optional extensions at MMCAP's sole discretion.